Aptevo Therapeutics Inc. (APVO)
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $3.1M
- Net income
- -$26.0M
- Total assets
- $27.2M
- Market cap
- $5.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$26.3M
- Income tax
- $0
- Net income
- -$26.0M
- EPS (basic)
- $-87.27
- EPS (diluted)
- $-87.27
Balance sheet
- Total assets
- $27.2M
- Current assets
- $23.1M
- Total liabilities
- $9.8M
- Current liabilities
- $6.0M
- Shareholders’ equity
- $17.4M
Cash flow
- Operating cash flow
- -$25.6M
- Investing cash flow
- -$12.9M
- Financing cash flow
- $38.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.9M
- EPS (diluted)
- $-87.27
- Shares outstanding
- 1.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 20, 2016
Aptevo Therapeutics Inc. (APVO) Stock Price
- Reported a net loss of $26.0M in FY2022.
- Trading 94% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aptevo Therapeutics Inc..
Write a review
News about Aptevo Therapeutics Inc.
News & sentiment via Polygon.io
Aptevo Therapeutics Inc.: frequently asked questions
Is Aptevo Therapeutics Inc. an American company?
Aptevo Therapeutics Inc. is a US-based company headquartered in Seattle, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aptevo Therapeutics Inc. headquartered?
Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, United States.
Is Aptevo Therapeutics Inc. publicly traded?
Yes — Aptevo Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol APVO on the NASDAQ.
What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
